SCHEMBL420801

SCHEMBL420801

CC1=NN(c2cccc(F)c2)C(=O)/C1=C\c1ccc(N(C)C)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 13/20 1.00
MEN1 O00255 12/20 1.00
MAPT P10636 6/20 0.57
L3MBTL1 Q9Y468 5/20 0.57
TDP1 Q9NUW8 3/20 0.57
MAPK1 P28482 2/20 0.57
LMNA P02545 1/20 0.57
PKM P14618 1/20 0.57
OPRK1 P41145 1/20 0.57
HTT P42858 1/20 0.57
GAA P10253 2/20 0.54
ALDH1A1 P00352 5/20 0.53
ALPL P05186 1/20 0.53
ALPI P09923 1/20 0.53
ALPG P10696 1/20 0.53
HPGD P15428 1/20 0.52
POLB P06746 1/20 0.50
PSMD14 O00487 1/20 0.47
KAT8 Q9H7Z6 1/20 0.47
AMY1A P0DUB6 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL444132 1.00 KMT2A (1.00) KMT2AMEN1MAPTL3MBTL1TDP1
SCHEMBL444133 1.00 KMT2A (1.00) KMT2AMEN1MAPTL3MBTL1TDP1
SCHEMBL10035978 0.87 KMT2A (0.76) KMT2AMEN1MAPTL3MBTL1TDP1
SCHEMBL29045556 0.79 KMT2A (0.76) KMT2AMEN1MAPTL3MBTL1TDP1
SCHEMBL29045554 0.79 KMT2A (0.76) KMT2AMEN1MAPTL3MBTL1TDP1
SCHEMBL9854202 0.78 MEN1 (0.64) KMT2AMEN1MAPTL3MBTL1TDP1
SCHEMBL9854204 0.78 MEN1 (0.64) KMT2AMEN1MAPTL3MBTL1TDP1
SCHEMBL12589929 0.77 KMT2A (0.65) KMT2AMEN1MAPTL3MBTL1TDP1
SCHEMBL14408191 0.77 KAT8 (0.76) KMT2AMEN1MAPTL3MBTL1TDP1
SCHEMBL5706389 0.77 KAT8 (0.76) KMT2AMEN1MAPTL3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140335517-A1 DETECTION AND TREATMENT OF SCHIZOPHRENIA RENASCIENCE CO LTD (JP) 2014-11-13 US disclosed
US-20140335517-A1 DETECTION AND TREATMENT OF SCHIZOPHRENIA RENASCIENCE CO LTD (JP) 2014-11-13 US disclosed
US-8809329-B2 Detection and treatment of schizophrenia TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (JP) 2014-08-19 US disclosed
US-8809329-B2 Detection and treatment of schizophrenia TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (JP) 2014-08-19 US disclosed
US-20120065198-A2 Detection and Treatment of Schizophrenia TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2012-03-15 US disclosed
US-20120065198-A2 Detection and Treatment of Schizophrenia TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2012-03-15 US disclosed
US-20110028470-A1 Detection and Treatment of Schizophrenia TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2011-02-03 US disclosed
US-7645882-B2 Inhibitor of protein modification products formation TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2010-01-12 US disclosed
US-7645882-B2 Inhibitor of protein modification products formation TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2010-01-12 US disclosed
US-20070123577-A1 Inhibitor of protein modification products formation TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2007-05-31 US disclosed
US-20070123577-A1 Inhibitor of protein modification products formation TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123577-A1 Inhibitor of protein modification products formation SERPINB6, PROC, PLPBP KMT2A 2334/4885MEN1 1277/4885MAPT 3796/4885
US-20110028470-A1 Detection and Treatment of Schizophrenia GLO1, CBR1, AOX1 KMT2A 1703/4885MEN1 4818/4885MAPT 4131/4885
US-20120065198-A2 Detection and Treatment of Schizophrenia GLO1, CBR1, AOX1 KMT2A 1703/4885MEN1 4818/4885MAPT 4131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.